Core Insights - Rippling, an HR software startup, raised $450 million in Series G funding, achieving a valuation of $16.8 billion, focusing on global revenue growth over immediate profitability [1][4][5] Funding and Valuation - The funding round included participation from notable investors such as Y Combinator, Elad Gil, Sands Capital, GIC, and Goldman Sachs Growth [2] - The new valuation of $16.8 billion marks an increase from the previous valuation of $13.5 billion in early 2024 [4] Employee Equity and IPO Plans - Rippling plans to repurchase up to $200 million of equity from current and former employees through a tender offer, which may become an annual event [2][3] - The CEO stated that the company does not have immediate plans for an IPO, emphasizing the need for profitability before considering going public [4][6] Business Performance and Strategy - Rippling has surpassed $100 million in annual recurring revenue and serves over 20,000 customers with a suite of more than 20 products [5] - The company is prioritizing growth over profitability, indicating a strategic choice to expand rapidly rather than slow down for immediate profit [6] Legal Challenges - Rippling is involved in ongoing legal disputes with competitor Deel, including allegations of corporate espionage, which have raised questions about competitive practices in the tech industry [7][8]

PresentationI would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.Please note, this event is being recorded.Good evening, and welcome to the Boston Scientific American College of Cardiology Conference Call.Lauren TenglerDirector of Investor Relations Thanks, Drew. Thanks to everyone for joining us. With me to discuss our CHAMPION-AF and HI-PEITHO trials are Dr. Ken Stein, our Chief Medical Officer; Dr. Michael Jaff, Chief Medical Officer, Vascula ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm Mar 29, 2026 12:13 AM Eastern Daylight Time IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm Share This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts The Schall Law Firm Brian Schall, Esq., www.schallfirm.comOffice: 310-301-3335 info@schallfirm.com LOS ANGELES- ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Past performance is not an indicator of future performance. This post is illustrative and educational ...

I am a Licensed Professional Engineer who works in the Nuclear Power industry. I use my professional working knowledge of the power/energy industries to aid in evaluating potential equities worthy of long-term investment. I invest in income producing equities and rental real estate properties for cash flow and long-term appreciation. My articles are to serve as a platform for presenting the underlying fundamentals and long-term potential of each equity/business.Analyst’s Disclosure: I/we have a beneficial l ...

I have already written some controversial articles with fervent comments, some with a slightly more offensive tone and others just disagreeing with arguments (feel free to comment on this one as well, especially if you have a differentEquity Research Analyst with a broad career in the financial market, covered both Brazilian and global stocks. As a value investor, my analysis is primarily fundamental, focusing on identifying undervalued stocks with growth potential. Feel free to reach out for collaborations ...

If you like to see more ideas, please subscribe to the Investing Group "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!At the start of the year, I concluded that eBay ( EBAY ) was both improving and fully re-rated at the same time. Shares had seen a spectacular re-rating in recent years, albeit from a low valuatio ...

Elon Musk‘s last original co-founder at xAI, Ross Nordeen, has reportedly resigned. This marks the end of an era for the company, which is now undergoing a major reorganization as it prepares for a high-profile IPO.Last Original Co-Founder Departs xAINordeen, one of the 11 co-founders who helped launch xAI with Musk, has left the company, Business Insider reported, citing sources.The 36-year-old had experience in high-performance computing and artificial intelligence systems from his work at Tesla (NASDAQ:T ...

WMK Investors Have Opportunity to Join Weis Markets, Inc. Fraud Investigation with the Schall Law Firm Mar 28, 2026 11:38 PM Eastern Daylight Time WMK Investors Have Opportunity to Join Weis Markets, Inc. Fraud Investigation with the Schall Law Firm Share LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Weis Markets, Inc. ("Weis Markets†or "the Company†) (NYSE: WMK) for violations of the s ...